Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

GlobeNewswireDec 20 05:15

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Zacks Dec 17 18:30

Myriad Genetics Is Maintained at Underperform by B of A Securities

Dow JonesDec 14 00:25 · Ratings

Myriad Genetics Analyst Ratings

BenzingaDec 14 00:14 · Ratings

BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $13

Futu NewsDec 13 21:33 · Ratings

Top Premarket Decliners

MT NewswiresDec 12 20:51